Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinaciclib in Advanced Malignant Melanoma
NCT01026324Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2009
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dinaciclib in Malignant Melanoma (MM), sponsored by National Cancer Institute. Started Sep 2009; status: terminated.
02
Drugs
dinaciclib
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01026324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01026324.